The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2

European Archives of Oto-Rhino-Laryngology

Volumn 272, Issue 12, 2014, Pages 3627-3633

  Alanin, Mikkel Christian ^a   Klausen, Camilla ^a   Caye Thomasen, Per ^a,b   Thomsen, Carsten ^a,b   Fugleholm, Kaare ^a   Poulsgaard, Lars ^a   Lassen, Ulrik ^a   Mau Sorensen, Morten ^a   Hofland, Kenneth Francis ^a  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Avastin; Bevacizumab; NF2; Vestibular schwannoma

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ACOUSTIC NEURINOMA; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; INTRACRANIAL HYPERTENSION; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEUROFIBROMATOSIS TYPE 2; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURE TONE AUDIOMETRY; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; YOUNG ADULT; AUDIOMETRY; CANCER STAGING; CEREBRAL HEMORRHAGE; DRUG EFFECTS; HEARING; METABOLISM; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; AUDIOMETRY; BEVACIZUMAB; CEREBRAL HEMORRHAGE; FEMALE; HEARING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84946497961     PISSN: 09374477     EISSN: 14344726     Source Type: Journal    
DOI: 10.1007/s00405-014-3398-3     Document Type: Article

References (20)

1. Peyre M, Goutagny S, Bah A, Bernardeschi D, Larroque B, Sterkers O, Kalamarides M (2013) Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. Neurosurgery 72:907–913
2. Caye-Thomasen P, Werther K, Nalla A, Bog-Hansen TC, Nielsen HJ, Stangerup SE, Thomsen J (2005) VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 26:98–101
3. Caye-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup SE (2003) Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 113:2129–2134
4. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso TE (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358–367
5. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046–1052
6. Eminowicz GK, Raman R, Conibear J, Plowman PN (2012) Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. J Laryngol Otol 126:79–82
7. Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12:14–18
8. Hawasli AH, Rubin JB, Tran DD, Adkins DR, Waheed S, Hullar TE, Gutmann DH, Evans J, Leonard JR, Zipfel GJ, Chicoine MR (2013) Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 74:136–141
9. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603–618
10. (1994) National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11–13, 1991. The Consensus Development Panel. Arch Neurol 51:201–207
11. (1995) Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC. Otolaryngol Head Neck Surg 113:179–180
12. Plotkin SR, Halpin C, Blakeley JO, Slattery WH III, Welling DB, Chang SM, Loeffler JS, Harris GJ, Sorensen AG, McKenna MJ, Barker FG (2009) Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 93:61–77
13. Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG (2010) Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 31:1135–1143
14. Springborg JB, Fugleholm K, Poulsgaard L, Caye-Thomasen P, Thomsen J, Stangerup SE (2012) Outcome after translabyrinthine surgery for vestibular schwannomas: report on 1244 patients. J Neurol Surg B Skull Base 73:168–174
15. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740
16. Lesley WS, Thomas MR, Abdulrauf SI (2004) N-butylcyanoacrylate embolization of a middle meningeal artery aneurysm in a patient with neurofibromatosis type 2. Am J Neuroradiol 25:1414–1416
17. Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR (2014) Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 73:1197–1204
18. Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X (2014) An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 9:e89960
19. Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS (2011) A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw 9:414–427
20. Plotkin SR, Merker VL, Muzikansky A, Barker FG, Slattery W III (2014) Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol 35:e50–e56